key: cord-0788916-4wlmht5z authors: Girardin, François; Manuel, Oriol; Marzolini, Catia; Buclin, Thierry title: Evaluating the risk of drug-drug interactions with pharmacokinetic boosters: the case of ritonavir-enhanced nirmatrelvir to prevent severe COVID-19. date: 2022-03-28 journal: Clin Microbiol Infect DOI: 10.1016/j.cmi.2022.03.030 sha: 553ec01febab84f3842e514d1dd1bbecea24c06b doc_id: 788916 cord_uid: 4wlmht5z nan The concept of pharmacokinetic enhancement can be traced back to the 1940s when probenecid was added to extend penicillin exposure. It revived in the 1990s with the advent of HIV combined antiretroviral therapies, when ritonavir was shown to markedly increase the circulating concentrations of saquinavir and other HIV protease inhibitors. Along with cobicistat, ritonavir remains widely used as a booster to leverage the effectiveness of co-administered antiretrovirals: both substances are potent cytochrome P450 inhibitors that reduce metabolic activity, extend drug half-lives, and improve the bioavailability of a wide range of concomitant drugs at sustained plasma concentrations. At 100 mg twice daily, ritonavir causes a strong inhibition of intestinal and hepatic CYP3A4 and p-glycoprotein (P-gp). Nirmatrelvir (PF-07321332), a CYP3A4 substrate, is a new peptidomimetic inhibitor of SARS-CoV-2 main protease (Mpro), which blocks the polyprotein precursors and prevents viral replication: [1] nirmatrelvir (NMV) combined with ritonavir (NMV/r) is assessed in phase 3 trials as an early therapeutic agent for patients at risk for COVID-19-related complications. Data supporting the emergency use authorization for NMV/r (Paxlovid™) are from EPIC-HR, a randomized, double-blind, placebo-controlled clinical trial in non-hospitalized symptomatic adults with a diagnosis of SARS-CoV-2 infection. NMV/r administered within three days of symptom onset reduced the risk of COVID-19 related hospitalization and death from any cause by 88%, compared to placebo. [2] Issues with pharmacokinetic boosters NMV 300 mg and ritonavir 100 mg (Paxlovid™), in two separate tablets, are administered twice daily for five days in patients with mild to moderate COVID-19 to prevent progression to severe disease. The boosting effect of ritonavir causes strong inhibition of the key drug metabolizing enzyme, CYP3A4. NMV/r has the potential to cause detrimental drug-drug interactions (DDI) notably with sensitive CYP3A4 or P-gp substrates or narrow therapeutic index drugs. [3] [4] Ritonavir is, already at low dose, a strong inhibitor of CYP3A4/5 and P-gp, and, to a lesser extent, of CYP2D6. [5] By contrast, ritonavir induces CYP1A2, CYP2B6, CYP2C9, and CYP2C19, as well as UDP-glucuronyl transferases. [3] However, since induction occurs slowly (i.e. generally 10-15 days after initiation of inducer), NMV/r is not anticipated to cause significant DDIs as an inducer, due to its short treatment course. On the other hand, NMV/r can be impacted by strong CYP P450 inducers (i.e. St. John's wort, antituberculosis drugs (rifampicin, rifapentine), and anticonvulsants (carbamazepine, phenobarbital, phenytoin). Importantly, DDI with strong inducers cannot be avoided by pausing inducers due to the persisting inducing effect (i.e. approximately two weeks) after stopping a strong inducer. Thus, J o u r n a l P r e -p r o o f patients on strong inducers would not qualify for NMV/r treatment. Alternative COVID-19 treatments should be considered in this situation, such as sotrovimab, remdesivir or molnupiravir. NMV/r is used for a short time (five days), primarily in outpatients as post-exposure or therapeutic treatment of mild to moderate COVID-19. In spite of the short treatment duration, the propensity for DDI is clinically significant due to the rapid onset of cytochromes inhibition by ritonavir (i.e. reaching maximal inhibition 48 hours after ritonavir initiation). By contrast, the induction of enzymatic activity develops progressively and more slowly than inhibition due to nuclear receptormediated transcriptional regulatory processes. The most clinically relevant DDI with MNV/r will be with medications predominantly metabolized by CYP3A4 (i.e. sensitive CYP3A4 substrates with narrow therapeutic index) and with sensitive substrates of P-gp. Drug classes of particular concern are those prone to concentration-dependent toxicities or lack of efficacy (Type A adverse drug events), including immunosuppressant drugs, such as mTOR inhibitors (everolimus, sirolimus) and calcineurine inhibitors (tacrolimus, cyclosporine), [6] oral anticoagulants (rivaroxaban, apixaban), antiplatelets (clopidogrel, ticagrelor), amiodarone, some statins (simvastatin, lovastatin), atypical antipsychotics (quetiapine, aripiprazole), benzodiazepines (midazolam, triazolam, diazepam), antimigraine agents, sildenafil, herbal (St. John's wort), and recreational drugs (amphetamines, ecstasy). Further interactions may affect hospitalized patients (e.g. opioids, anesthetics, anticancer treatments, such as vinca alkaloids or taxol derivatives), and some anti-tuberculosis agents. All these drugs are often prescribed to patients susceptible to be at risk of complications from SARS-CoV-2 infection, and thus candidate to receive a course of NMV/r over their usual treatment. [7] Reconstituting the medication history can be difficult and time consuming in patients with polypharmacy. Some patients might not readily acknowledge their reliance on psychotropic agents, erectile function enhancers or complementary medicines. We expect that NMV/r will be essentially given to outpatients but also to hospitalized patients: preemptive measures to contain DDI could be particularly challenging to implement, given the need to manage dosing adjustment/monitoring quickly and for a short time period. [8] Medication reconciliation and DDI screening using specialized resources or expert consultation is advised before prescribing NMV/r. Up-to-date interaction checkers such as the online tool COVID-19 DDIs checker by the Liverpool Drug Interaction Group are of utmost usefulness for this task. [9] For drugs requiring impractical dosing adjustment/monitoring, the DDI concerns associated with ritonavir will need to take into account the risk-benefit of prescribing NMV/r to prevent severe COVID-19. If some medications have to be stopped during NMV/r treatment, prescribers should be J o u r n a l P r e -p r o o f aware that CYP3A4 inhibition takes a few days to resolve. [10] According to updated DDI recommendations, paused medications can be resumed three days following the last dose of NMV/r. [9] We would strongly recommend utmost caution with the wide scale prescription of NMV/r, given its high potential to cause DDI: straightforward and easily understandable warnings on drug categories should be mandatory to facilitate pre-emptive and thorough evaluation of any co-administered medication. Readily access to comprehensive patient treatments with treatment reconciliation will facilitate DDI screening using specialized resources. Step 1: establish the complete list with all current medications, including over-the counter drugs, herbal products, and recreational substances. Step 2: identify potential DDIs using specialized resources (e.g. www.covid19-druginteractions.org). Step 3: assess the risk/benefit of NMV/r treatment in presence of an interacting medication (Table 1 ). This assessment should take into account the risk of a given patient to develop a complicated COVID-19 course (risk is higher in immunocompromised patients elderly, see NIH COVID19 treatment website for other risky conditions). The following strategies should be considered when managing DDIs with NMV/r: i) pausing the comedication if it is clinically appropriate to do so; ii) monitoring or dose adjustment of the comedication (challenging to implement given the short treatment course of NMV/r); iii) switch comedication; iv) patient counselling about potential DDIs with advice to withhold temporarily a comedication if feeling unwell or v) use of alternative COVID-19 therapy (sotrovimab, remdesivir, molnupiravir) [8] . Neglecting these precautions could raise concerns and therapeutic promise of nirmatrelvir might be outweighed by the risk associated with its pharmacokinetic booster once this antiviral agent will be prescribed to patients in the real world. Author contributions All authors wrote the original draft. FG, OM and CM conceptualized the table. All authors contributed to review and editing. Supervised Molecular Dynamics (SuMD) Insights into the mechanism of action of SARS-CoV-2 main protease inhibitor PF-07321332 Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 Cobicistat versus ritonavir boosting and differences in the drugdrug interaction profiles with co-medications Physiologically-Based Pharmacokinetic Modeling to Support the Clinical Management of Drug-Drug Interactions With Bictegravir Characterization of ritonavir-mediated inactivation of cytochrome P450 3A4 Nirmatrelvir/ritonavir use: Managing clinically significant drug-drug interactions with transplant immunosuppressants Caution required with use of ritonavir-boosted PF-07321332 in COVID-19 management Prescribing Nirmatrelvir-Ritonavir: How to Recognize and Manage Drug-Drug Interactions COVID-19 drug interaction checker Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect COVID19 treatment guidelines J o u r n a l P r e -p r o o f Table 1 : Risk of drug-drug interactions with nirmatrelvir/ritonavir and recommended drug-drug interaction. Note that the inhibitory effect of ritonavir needs 72 h after discontinuation to resolve. The classification of the drug-drug interactions refers to the University of Liverpool COVID19 drug interaction resource: www.covid19-druginteractions.org.